Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Neurosurgery

• Publication date

  2005-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3171/JNS.2005.103.1.0156PMID 16121986
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Electrofusion

  2007cited by this paper
• Comparative Analysis of Antigen Loading Strategies of Dendritic Cells for Tumor Immunotherapy

  2004cited by this paper
• Memory T Cells Originate from Adoptively Transferred Effectors and Reconstituting Host Cells after Sequential Lymphodepletion and Adoptive Immunotherapy1

  2004cited by this paper
• γ-Irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells

  2004cited by this paper
• The History, Evolution, and Clinical use of Dendritic Cell-Based Immunization Strategies in the Therapy of Brain Tumors

  2004cited by this paper
• Gene expression profiling identifies molecular subtypes of gliomas

  2003cited by this paper
• Dendritic cell-based cancer immunotherapy.

  2003cited by this paper
• Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine.

  2003cited by this paper
• Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model.

  2003cited by this paper
• Magnetic resonance image–guided proteomics of human glioblastoma multiforme

  2003cited by this paper
• Therapeutic efficacy of adoptive immunotherapy is predicated on in vivo antigen-specific proliferation of donor T cells.

  2003cited by this paper
• Hybrids of Dendritic Cells and Tumor Cells Generated by Electrofusion Simultaneously Present Immunodominant Epitopes from Multiple Human Tumor-Associated Antigens in the Context of MHC Class I and Class II Molecules1

  2003cited by this paper
• Thymic function and output of recent thymic emigrant T cells during intracranial glioma progression

  2003cited by this paper
• Drug- and cell-mediated antitumor cytotoxicities modulate cross-presentation of tumor antigens by myeloid dendritic cells

  2003cited by this paper
• Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients.

  2003cited by this paper
• Dendritic cell-based cancer therapy.

  2003cited by this paper
• Thymic CD8+ T Cell Production Strongly Influences Tumor Antigen Recognition and Age-Dependent Glioma Mortality 1

  2003cited by this paper
• The use of dendritic cells in cancer immunotherapy.

  2003cited by this paper
• The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors

  2003cited by this paper
• Cutting Edge: Cross-Presentation as a Mechanism for Efficient Recruitment of Tumor-Specific CTL to the Brain 1

  2003cited by this paper
• Therapeutic immune response induced by electrofusion of dendritic and tumor cells.

  2002cited by this paper
• Identification of a Novel HLA-A * 0201-restricted , Cytotoxic T Lymphocyte Epitope in a Human Glioma-associated Antigen , Interleukin 13 Receptor 2 Chain 1

  2002cited by this paper
• Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion.

  2002cited by this paper
• Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain.

  2002cited by this paper
• Identification of a Novel HLA-A*0201-restricted, Cytotoxic T Lymphocyte Epitope in a Human Glioma-associated Antigen, Interleukin 13 Receptor α2 Chain

  2002cited by this paper
• Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication.

  2002cited by this paper
• Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials.

  2002cited by this paper
• Equipotent Generation of Protective Antitumor Immunity by Various Methods of Dendritic Cell Loading With Whole Cell Tumor Antigens.

  2001cited by this paper
• Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity.

  2001cited by this paper
• Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.

  2001cited by this paper
• Equipotent Generation of Protective Antitumor Immunity by Various Methods of Dendritic Cell Loading With Whole Cell Tumor Antigens

  2001cited by this paper
• Antitumor Effect of Immunizations With Fusions of Dendritic and Glioma Cells in a Mouse Brain Tumor Model

  2001cited by this paper
• Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model.

  2001cited by this paper
• Augmentation Versus Inhibition: Effects of Conjunctional OX-40 Receptor Monoclonal Antibody and IL-2 Treatment on Adoptive Immunotherapy of Advanced Tumor1

  2001cited by this paper
• PHF3-specific antibody responses in over 60% of patients with glioblastoma multiforme

  2001cited by this paper
• Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells

  2001cited by this paper
• T cell adoptive immunotherapy of newly diagnosed gliomas.

  2000cited by this paper
• Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway.

  2000cited by this paper
• Cross-Presentation of Tumor Antigens to Effector T Cells Is Sufficient to Mediate Effective Immunotherapy of Established Intracranial Tumors1

  2000cited by this paper
• Dendritic cells in cancer immunotherapy.

  2000cited by this paper
• Astrocytoma infiltrating lymphocytes include major T cell clonal expansions confined to the CD8 subset.

  1999cited by this paper
• Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy.

  1999cited by this paper
• Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers.

  1999cited by this paper
• Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens.

  1999cited by this paper
• Systemic T cell adoptive immunotherapy of malignant gliomas.

  1998cited by this paper
• Dendritic cells and the control of immunity

  1998cited by this paper
• Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

  1998cited by this paper
• Bone marrow‐derived dendritic cells pulsed with a tumor‐specific peptide elicit effective anti‐tumor immunity against intracranial neoplasms

  1998cited by this paper
• Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas.

  1997cited by this paper
• Innate Immunity: The Virtues of a Nonclonal System of Recognition

  1997cited by this paper
• Bone Marrow–generated Dendritic Cells Pulsed with Tumor Extracts or Tumor RNA Induce Antitumor Immunity against Central Nervous System Tumors

  1997cited by this paper
• Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells.

  1997cited by this paper
• Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.

  1996cited by this paper
• Defining the synergistic effects of irradiation and T-cell immunotherapy for murine intracranial tumors.

  1996cited by this paper
• Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas.

  1995cited by this paper
• Electrofusion.

  1993cited by this paper
• Effect of the expression of transforming growth factor-beta 2 in primary human glioblastomas on immunosuppression and loss of immune surveillance.

  1992cited by this paper
• Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.

  1991cited by this paper
• Gamma-irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells.

  1984cited by this paper
• Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.

  1980cited by this paper
• Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial.

  1978cited by this paper
• Studies on the chemotherapy of experimental brain tumors: development of an experimental model.

  1970cited by this paper
• The treatment of glioblastoma multiforme of the brain.

  1967cited by this paper
• Quantitative studies on tissue transplantation immunity. II. The origin, strength and duration of actively and adoptively acquired immunity

  1954cited by this paper

• Advancements in noninvasive visualization of the immune environment in glioblastoma: A systematic review

  2025cites this paper
• Chemotherapy Can Synergize With Adoptive Immunotherapy to Inhibit Medulloblastoma Growth

  2022cites this paper
• Whole-body PET Imaging of T-cell Response to Glioblastoma

  2021cites this paper
• Neoplastic Brain, Glioblastoma, and Immunotherapy

  2020cites this paper
• A case of pediatric paraspinal arteriovenous fistula with multiple fistulas

  2020cites this paper
• T lymphocyte-targeted immune checkpoint modulation in glioma

  2020cites this paper
• Radiation as an In Situ Auto-Vaccination: Current Perspectives and Challenges

  2019cites this paper
• Oncoproteins Targeting: Antibodies, Antisense, Triple-helix. Case of Anti IGF-I Cancer Immunogene Therapy

  2019cites this paper
• In vitro Technical Aspects of Anti-Gene IGF-I Vaccines against Glioma

  2019cites this paper
• Twenty-Five Years of Cancer Immunogene Therapy: Anti - Gene IGF-I Approach

  2019cites this paper
• Post-Surgery of Glioma, Delirium and Anti IGF-I Therapy

  2019cites this paper
• Applied physiology of IGF-I: case reports of gene therapy of malignant tumors especially glioma.

  2018cites this paper
• Brain stem cells and IGF-I: implications in development, regeneration and cancer therapeutics

  2018cites this paper
• Targeting the immune system in glioblastoma

  2017cites this paper
• Combining Radiotherapy and Immunotherapy

  2017cites this paper
• 9 Combination of Immunotherapy & Radiotherapy for the Treatment of Prostate Cancer

  2017cites this paper
• Anti - Gene IGF-I Technology applied for Cancer Immunotherapy

  2016cites this paper
• Prognostic factors influencing clinical outcomes of malignant glioblastoma multiforme: clinical, immunophenotypic, and fluorescence in situ hybridization findings for 1p19q in 816 chinese cases.

  2015cites this paper
• Active dendritic cell immunotherapy for glioblastoma: Current status and challenges

  2015cites this paper
• Overview of current immunotherapeutic strategies for glioma.

  2015cites this paper
• OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal

  2015cites this paper
• Dendritic cell immunotherapy for glioblastoma

  2014cites this paper
• Dendritic cell-glioma fusion activates T lymphocytes by elevating cytotoxic efficiency as an antitumor vaccine

  2014cites this paper
• Immunotherapy of Malignant Tumors Using Antisense Anti-IGF-I Approach: Case of Glioblastoma

  2014cites this paper
• DCVax®-L—Developed by Northwest Biotherapeutics

  2014cites this paper
• Radixin knockdown by RNA interference suppresses human glioblastoma cell growth in vitro and in vivo.

  2014cites this paper
• Targeting Tregs in Malignant Brain Cancer: Overcoming IDO

  2013cites this paper
• Cancer stem cell vaccination confers significant antitumor immunity.

  2012cites this paper
• Methodology for Anti-Gene Anti-IGF-I Therapy of Malignant Tumours

  2012cites this paper
• The impact of intraoperative vaccination with IL-12 modified autologous tumor cells in the Lewis lung carcinoma mouse model

  2012cites this paper
• Immunotherapy for glioma: promises and challenges.

  2012cites this paper
• Tumor and Stem Cell Biology Cancer Stem Cell Vaccination Confers Signi fi cant Antitumor Immunity

  2012cites this paper
• Erratum to “Methodology for Anti-Gene Anti-IGF-I Therapy of Malignant Tumours”

  2012cites this paper
• Treatment of Melanoma with Agonist Immune Costimulatory Agents

  2012cites this paper
• Antisense Oligonucleotides in the Treatment of Malignant Gliomas

  2012cites this paper
• immature dendritic cells in a vaccination setting T-cell immunity by + Costimulatory ligand CD70 allows induction of CD8

  2012cites this paper
• Immunity Cancer Stem Cell Vaccination Confers Significant Antitumor

  2012cites this paper
• Preparation and identification of a novel immunomodulator composed of muramyl dipeptide and anti-CD10 monoclonal antibody for treatment of minimal residual disease in acute leukemia children.

  2011cites this paper
• Dendritic cell-tumor cell hybrids and immunotherapy: what's next?

  2011cites this paper
• Immune response to cancer and its regulation in regional lymph nodes

  2011cites this paper
• Dendritic cell-tumor cell fusion vaccines.

  2011cites this paper
• Dendritic cell-based tumor vaccination for high-grade gliomas

  2011cites this paper
• High-Grade Gliomas: Dendritic Cell Therapy

  2011cites this paper
• Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model

  2011cites this paper
• Combination of Immunotherapy & Radiotherapy for the Treatment of Prostate Cancer

  2011cites this paper
• Biologic principles of immunotherapy for malignant gliomas.

  2010cites this paper
• Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study

  2010cites this paper
• Overview of Cellular Immunotherapy for Patients with Glioblastoma

  2010cites this paper
• Dendritic Cell Therapy of High‐Grade Gliomas

  2009cites this paper
• Targeting the CD134–CD134L interaction using anti-CD134 and/or rhCD134 fusion protein as a possible strategy to prevent lupus nephritis

  2009cites this paper
• Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments

  2009cites this paper
• Antisense anti-IGF-I therapy of primary hepatic cancer

  2009cites this paper
• Costimulatory ligand CD70 allows induction of CD8+ T-cell immunity by immature dendritic cells in a vaccination setting.

  2009cites this paper
• Recent Advances of Dendritic Cells (DCs)-Based Immunotherapy for Malignant Gliomas

  2009cites this paper
• Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12.

  2008cites this paper
• Harnessing T-Cell Immunity to Target Brain Tumors

  2008cites this paper
• High-flow Paraspinal Osseous Epidural Arteriovenous Fistula

  2008cites this paper
• Significance of regional draining lymph nodes in the development of tumor immunity: implications for cancer immunotherapy.

  2007cites this paper
• Immunotherapy for Gliomas: Part II Passive Immunotherapy and Active Immunotherapy

  2007cites this paper
• Immunogenicity of dendritic-tumor fusion hybrids and their utility in cancer immunotherapy.

  2007cites this paper
• An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.

  2007cites this paper
• Induction of tumor antigen-specific cytotoxic T cell responses in naïve mice by latex microspheres-based artificial antigen-presenting cell constructs.

  2007cites this paper
• Insulin-like growth factor type I biology and targeting in malignant gliomas.

  2007cites this paper
• Fusion of CpG-ODN-stimulating dendritic cells with Lewis lung cancer cells can enhance anti-tumor immune responses.

  2006cites this paper
• [Dendritic cells and gliomas: a hope in immunotherapy?].

  2006cites this paper
• DENDRITIC CELL VACCINATION IN PATIENTS WITH MALIGNANT GLIOMAS: CURRENT STATUS AND FUTURE DIRECTIONS

  2006cites this paper
• Cellules dendritiques et gliomes : un espoir en immunothérapie ?

  2006cites this paper
• Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination.

  2006cites this paper
• A NOVEL METHOD FOR OBTAINING OF DENDRITIC TUMOR FUSION CELLS ANTICANCER VACCINES

  2006cites this paper
• Immune responses in the draining lymph nodes against cancer: Implications for immunotherapy

  2006cites this paper